Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115190) titled 'Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals with Hyperlipidemia' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shanghai Tenth People's Hospital
Condition:
Eligible participants had a BMI of >= 24 kg/m^2 and dyslipidemia (TG >= 1.7 mmol·L^(-1) or TC >= 5.2 mmol·L^(-1)), and were free from major chronic conditions.
Intervention:
Trial group (spermidine):Spermidine capsules 10 mg/day
Recruitment Status: Not Recruiting
Phase: 0
Date of First Enrollment: 2025-12-2...